Interesting trading today so farInteresting to see the response against Pharmala stock after the FDA Panal review board gave a negative recommendation and Optimi is so far untouched by the news. Nick made it clear in the last interview that Pharmala will not be doing business in the US because if MDMA gets approved by the FDA then Lykos gets exclusivity in the US for the next 5 years anyways, so this FDA recommendation should have little effect on Pharmala. His focus is the other countries (i.e. currently Australia and Canada), but because Pharmala's patented MDMA derivatives do address some of the safety risk concerns brought up by the FDA panal regarding cardiovascular issues this actually makes Pharmala even more valuable to big pharma as Pharmala's MDMA molecule is patented and therefore money can be made for big Pharma with the rights to this drug. Clinical trials with Pharmala's MDMA molecule could now open the door for this company to be the MDMA molecule of choice for approval in the US. Pharmala actually just became more valuable. Those who sold may regret the sell.